AVATAR-HF (Artificial Voice Analysis and Telemonitoring for Heart Failure): Studio di fattibilità Sull'Uso Dell'Analisi Vocale Basata su Intelligenza Artificiale Per il Telemonitoraggio Dei Pazienti Con Insufficienza Cardiaca.

Heart failure is a serious condition and a major reason why older adults are admitted to the hospital. Even after going home, many patients struggle to get the follow-up care they need, leading to high rates of return to the hospital.
While remote monitoring technology exists, it is often difficult to use, expensive, or hard for doctors to interpret.
Recent research suggests that changes in a person's voice and speech can be early warning signs of worsening heart failure, but we need to test if this can work reliably in a home setting.This study tests a new, user-friendly platform called AVATAR-SC.
This system uses a a computer-generated character to interact with patients. By analyzing short voice clips and simple health questionnaires provided by the patient, the system aims to make home monitoring easier and more effective.
The study will involve 60 participants divided into two groups:half of the patients who have recently been discharged from the hospital following a heart failure episode; the other 30 patients who visit the hospital monthly for a specific heart failure treatment (Levosimendan).
Participants will interact with the digital avatar twice a week. During these sessions, they will provide brief voice recordings and answer a few questions about how they feel. It is important to note that the AI in this study is not making medical decisions or changing the patient's current treatment; it is strictly being tested to see how well the technology functions.
As a feasibility study, the primary goal is to evaluate the practical implementation of the technology rather than clinical outcomes.
The research focuses on: Determining if patients can navigate the system easily and independently, Assessing how consistently participants engage with the scheduled sessions, Verifying the technical reliability of the platform in a home environment,identifying the strengths and challenges of the system to prepare for future, larger-scale trials.
Benefits: Participants may feel more supported and more aware of their symptoms through regular check-ins.
Risks: The risks are very low. They mostly involve getting used to new technology and ensuring that personal data is kept private and secure.
Impact If successful, AVATAR-SC could lead to a new way for doctors to keep an eye on heart failure patients at home, catching problems early through the sound of their voice and preventing unnecessary hospital visits.

Start Date30 Oct 2026

Sponsor / Collaborator

Niguarda Hospital

CTRI/2026/07/114489

/ Not yet recruitingNot ApplicableIIT

Comparison of clinical outcomes of Levosimendan versus Milrinone following surgical closure of Ventricular Septal Defect A Prospective Randomised Study - NIL

Start Date03 Aug 2026

Sponsor / Collaborator-

CTRI/2026/04/109875

/ Not yet recruitingPhase 4

Echocardiographic and Biochemical Outcomes of Right Heart Dysfunction In Patients Undergoing Valve Replacement Surgery for Stenotic Lesions of the Mitral Valve A Therapeutic Comparison of Milrinone Vs Levosimendan - ECHOBIOM

Start Date18 May 2026

Sponsor / Collaborator-

100 Clinical Results associated with Levosimendan

100 Translational Medicine associated with Levosimendan

100 Patents (Medical) associated with Levosimendan

1,842

Literatures (Medical) associated with Levosimendan

01 Dec 2026·VETERINARY RESEARCH COMMUNICATIONS

Acute hemodynamic and echocardiographic responses to pimobendan versus levosimendan in a dog with decompensated dilated cardiomyopathy

Article

Author: Varlik, Tuğba ; Polat, Ela Nur ; Tanaka, Ryou ; Yilmaz, Zeki ; Sağ, Saim ; Algan, Didem

Dilated cardiomyopathy (DCM) is a major cause of systolic heart failure in dogs, characterized by ventricular dilation and reduced contractility. During acute decompensation, rapid inodilator therapy is essential to stabilize hemodynamics. This case describes serial changes in non-invasive blood pressure and left ventricular systolic function observed during sequential administration of two inodilator agents via different routes on consecutive days. An Anatolian shepherd dog was presented with acute respiratory distress. Echocardiography revealed severe left ventricular dilation and systolic dysfunction, and DCM was diagnosed using established criteria. Because oral therapy was initially not tolerated, intravenous pimobendan was administered, producing a rapid but transient improvement in systolic indices and global longitudinal strain (GLS). After transition to oral pimobendan the following day, systolic function improved mildly, while GLS remained markedly reduced. Levosimendan was subsequently administered as an intravenous bolus, resulting in only minimal improvement in systolic parameters and GLS. A continuous infusion was then initiated; however, systolic measurements remained largely unchanged during infusion. Serial echocardiographic assessment, particularly GLS, documented temporal changes in myocardial function during sequential inodilator therapy. These findings represent descriptive clinical observations from the management of a single patient and should not be interpreted as evidence of comparative efficacy or superiority of one inodilator over another. Because atrial fibrillation and temporal variation in heart rate may have influenced echocardiographic measurements throughout the monitoring period, the findings should be interpreted within the methodological limitations of this sequential single-case report.

01 Dec 2026·Journal of Cardiovascular Translational Research

Ventricle-Specific Biomechanical Responses to Inotropic and Vasoactive Drugs in Human Myocardial Slices

Article

Author: Meuwese, Christiaan L ; Bogers, Ad J J C ; Taverne, Yannick J H J ; Amesz, Jorik H ; Langmuur, Sanne J J ; Manintveld, Olivier C ; de Groot, Natasja M S ; Veen, Kevin M ; Alipour Symakani, Rahi S

Abstract:

This study aimed to compare baseline biomechanical contractile properties between right (RV) and left ventricular (LV) human living myocardial slices (LMS) and explore the effect of dobutamine, noradrenaline, adrenaline, levosimendan and enoximone in both ventricles. Sixty-three slices (33 RV, 30 LV) were produced from 5 explanted hearts. At baseline, RV LMS had a higher maximum contraction force, shorter contraction duration, time to peak and time to relaxation, steeper dF/dt and a larger peak area than LV LMS. Dobutamine administration had a larger effect in RV than LV LMS. Spontaneous, irregular contractions were observed after noradrenaline, adrenaline and dobutamine administration. In conclusion, RV LMS showed a stronger contraction with higher contraction velocity as compared to LV LMS and exhibited a greater response to dobutamine. These findings contribute to the understanding of the RV physiology as a separate entity, advocating for a different approach in treating RV or LV dysfunction.Graphical Abstract

01 Nov 2026·HEART

Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials

Article

Author: Sforza, Laura Moita ; Oliveira, Matheus dos Santos Silva de ; Parente, Hilson Amorim ; Magliano, Carlos ; Cordeiro, João Vitor Fazzio de Andrade ; Salgado, Diamantino Ribeiro

Background:

Acute decompensated heart failure (ADHF) with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties. This study aimed to compare the effects of levosimendan versus dobutamine on short-term clinical outcomes in patients with ADHF.

Methods:

We performed a systematic search of PubMed (MEDLINE), Embase and the Cochrane Library to identify randomised controlled trials (RCTs) comparing levosimendan and dobutamine in adults with ADHF. The primary outcome was all-cause mortality within 30 days. Secondary outcomes included length of hospital stay and improvement in glomerular filtration rate. Meta-analyses were conducted using a random-effects model.

Results:

Eight RCTs (n=1973) were included. Levosimendan significantly reduced 30-day mortality compared with dobutamine (OR 0.53, 95% CI 0.31 to 0.91; I² = 27%). Hospital stay was shortened by a mean of 2.4 days (95% CI –3.3 to –1.5), though heterogeneity was high. Limited data suggested renal function benefits. Certainty of evidence was moderate for mortality and very low for hospital stay.

Conclusions:

Levosimendan reduced short-term mortality and hospital stay compared with dobutamine in patients with ADHF, although the certainty of evidence was moderate for mortality and very low for hospital stay. Larger trials are needed to confirm these findings.

News (Medical) associated with Levosimendan

08 Sep 2026

·www.biospace.com

Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’

iStock, Mohammed Haneefa Nizamudeen After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-pro flops to six over nine weeks. Novo Nordisk is ending two more late-stage studies for its investigational IL-6 inhibitor, citing expected futility and dimming prospects for the class as a whole in cardiovascular disease. The early discontinuations are for a pair of Phase 3 heart failure studies called HERMES and ATHENA , a spokesperson told BioSpace in a Tuesday email. The Danish pharma’s decision to shutter the studies early was “based on a recommendation from the Data Monitoring Committee on the totality of the data (including the low likelihood of a different outcome from ZEUS),” the spokesperson added. At the end of July, Novo’s IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage ZEUS trial, dashing the pharma’s hopes for the heart inflammation program while also shaking other industry players working on the same pathway. “IL-6 now looks like an invalid target in chronic cardiovascular disease,” Oppenheimer analysts wrote on Tuesday. The industry had held out hope that the futility in ZEUS was potentially related to the trial’s population, which included patients with cardiovascular disease, chronic kidney disease and inflammation. Now, however, the futility terminations of both HERMES and ATHENA “remove the population-selection defense,” Oppenheimer said. HERMES enrolled nearly 5,000 patients with heart failure with mildly reduced ejection fraction and systemic inflammation, while ATHENA recruited 680 patients for the same type of heart failure. Immunology and inflammation Novo’s late-stage IL-6 stumble shakes inflammation space Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week’s Phase 3 failure dashed not just the Danish pharma’s hopes but that of other drugmakers working on the same pathway. August 3, 2026 · 2 min read · Tristan Manalac Read more With the addition of the two new trial fails, six total cardiovascular studies have flopped in just nine weeks, according to Oppenheimer. Beyond Novo’s three studies, AstraZeneca and Ionis Pharmaceuticals’ antisense oligonucleotide Wainua failed to significantly help patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), shaking the field’s confidence in the transthyretin silencer drug class. Most recently, Novartis’ antisense therapy pelacarsen showed no significant benefit on cardiovascular risk in a late-stage study. This outcome, analysts said, raises questions about a popular target for heart disease. When including Tenax Therapeutics’ late-stage flop for oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction, the findings have produced a narrative that cardiovascular outcome trials “are becoming unwinnable,” Oppenheimer said. But the analysts believe a deeper framing is needed, pointing to differences across the trials, such as attempts to treat different aspects of heart conditions and population variances. As for Novo, the obesity heavyweight is still waiting on results for another Phase 3 trial called ARTEMIS , which is testing ziltivekimab in the acute setting after heart attack. The study will continue as planned, with a readout slated for the first half of next year. “ARTEMIS remains active with lower expectations for success,” BMO analysts wrote Tuesday. The firm pointed to Novo’s Capital Markets Day, which will take place Sept. 21, as a near-term focus for investors. Novo’s stock has dipped 2% to $45.59 per share since market open on Tuesday. While Oppenheimer analysts were not entirely surprised about the new HERMES and ATHENA discontinuations, they did say they expect Novo shares “to be mildly pressured” by the announcement. Earnings Novo CEO sees innovation as a matter of survival amid pipeline setbacks Novo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its pipeline to move past recent clinical roadblocks. August 5, 2026 · 3 min read · Tristan Manalac Read more

Phase 3Oligonucleotide

01 Sep 2026

·www.biospace.com

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage . About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit . Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”. Contact: Investor and Media: Argot Partners tenax@argotpartners.com

Phase 3

29 Aug 2026

·www.globenewswire.com

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path CHAPEL HILL, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today announced that additional results from the Phase 3 LEVEL clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) were presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. Data confirmed findings from prespecified analyses which identified a favorable treatment effect in patients with a lower baseline 6MWD, supported by consistent changes in prespecified endpoints measuring cardiac stress and pulmonary pressures. “The independent analysis of LEVEL data we presented today sharpens what the earlier topline results initially indicated: patients with the lowest baseline walking distance had the greatest improvement, on top of state-of-the-art background therapy. What was particularly striking was that even patients who did not show a significant improvement in exercise capacity had the same magnitude of reduction in cardiac wall stress and pulmonary artery pressures, changes that correspond to a reduction in heart failure hospitalizations over longer follow-up,” said Sanjiv Shah, MD, Director of the HFpEF Program at Northwestern University Feinberg School of Medicine and LEVEL’s Principal Investigator. “The magnitude of the reduction in NT-proBNP and the accompanying lowering of pulmonary pressure indicate that TNX-103 may provide clinical benefit to the majority of patients with PH-HFpEF independent of its effect on walk distance. The data are compelling and consistently point toward a potential therapeutic benefit in PH-HFpEF patients.” “The full set of prespecified analyses we completed in the last week, and Dr. Shah’s presentation of the results today, continue to emphasize that the treatment effect of TNX-103 is concentrated in patients walking less than the trial median of 333 meters at baseline. The finding of biologic efficacy in the majority of patients in LEVEL validates that the unique mechanism of action demonstrated in the Phase 2 HELP study can address patient function. That gives us conviction and a clear strategy to enrich LEVEL-2 for a study population of patients in whom the treatment effect is demonstrable,” said Stuart Rich, MD, Chief Medical Officer of Tenax Therapeutics. “LEVEL has been enormously informative in shaping what comes next, and we intend to move quickly on behalf of patients who currently have no approved treatment options.” Key Takeaways from Late-Breaking Presentation The Phase 3 LEVEL clinical trial (NCT05983250) randomized 241 patients with PH-HFpEF across 41 sites in the United States and Canada. In this population, the primary endpoint of change in 6-minute walk distance (6MWD) at Week 12 did not achieve statistical significance, nor did the key secondary endpoint, change in Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS); however, marked improvements were noted in exploratory endpoints that demonstrate the biologic effects of the therapy, notably N-terminal pro-B-type natriuretic peptide (NT-proBNP) and right ventricular systolic pressure (RVSP). Several key observations made in the trial, and their potential influence on the future development of levosimendan for patients with pulmonary hypertension and heart failure, were emphasized: Across the overall trial population (n = 241), TNX-103 was safe and well tolerated, with no significant arrhythmias.This population of older, symptomatic patients presented with multiple comorbidities, and was well-treated on guideline-directed medical therapy (GDMT): across these categories of increasing disease severity, with emphasis placed on atrial fibrillation and exercise tolerance, and increasing therapeutic intervention like MRAs/diuretics, and SGLT-2 inhibitors, levosimendan’s benefit appears to increase.An inverse linear relationship between baseline 6MWD and treatment effect was described and demonstrated not to be explained by regression to the mean. Patients in LEVEL whose baseline 6MWD match those reported in HELP and the recent CADENCE trial with sotatercept (274-285 meters) demonstrated an approximate 20-meter placebo-adjusted improvement in 6MWD. The overall trial population in LEVEL, however, had a median about 50-60 meters higher than in these previous PH-HFpEF trials.Prognostic implications include the impact of levosimendan on NT-proBNP compared to multiple classes of heart failure therapies, including some currently being tested, with commentary of the magnitude of effect in relation to heart failure events. As noted in the presentation, no data from a Phase 3 randomized trial has demonstrated even half the impact on this key indicator of cardiac wall stress, when compared to placebo. In an analysis of the relationship between heart failure outcomes and NT-proBNP change across these classes, Dr. Shah noted that the magnitude of levosimendan’s effect on cardiac wall stress suggests potential impact on outcomes in these HFpEF patients.In addition to RVSP, many echocardiographic endpoints show improvement with levosimendan compared to placebo. Across each domain of echocardiography, approximately 20 echocardiographic parameters improved, even when adjusting for multiple comparisons. Dr. Shah referenced these results in the prespecified subgroup of patients with a baseline 6MWD below the trial median of 333 meters (n = 119), at Week 12: 6MWD: least-squares mean change was +23.7 meters on TNX-103 versus −2.6 meters on placebo; treatment difference of +26.3 meters (p = 0.0112).KCCQ-TSS: change was +9.8 points on TNX-103 versus +4.1 points on placebo; a 5-point threshold is generally considered clinically meaningful.RVSP: change of −4.4 mmHg on TNX-103 versus +0.5 mmHg on placebo; treatment difference −4.9 mmHg (p = 0.009). (post-hoc analysis)NT-proBNP: geometric least-squares mean ratio of 0.53 from baseline on TNX-103 (p < 0.0001), corresponding to a 47% reduction compared to placebo. (post-hoc analysis) The Company intends that the LEVEL-2 population be enriched on the basis of clear evidence provided by the LEVEL results, and in a manner consistent with longstanding FDA guidance for sponsors. Tenax will continue to focus on the global development of this product for patients with high unmet need. About Levosimendan (TNX-101, TNX-102, TNX-103) Levosimendan is a novel, first-in-class K-ATP channel activator/calcium sensitizer currently being evaluated to treat pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF). Levosimendan was first developed for intravenous use in hospitalized patients with acutely decompensated heart failure, and it has received market authorization in 60 countries in this indication, although it is not available in the United States or Canada. Tenax’s Phase 2 HELP study, including its open-label extension stage, demonstrated the potential of IV (TNX-101) and oral (TNX-103) levosimendan to bring durable improvements in exercise capacity and quality of life, as well as other clinical assessments, in patients with PH-HFpEF. TNX-103 (oral levosimendan) is currently being evaluated in LEVEL-2, a Phase 3, double-blind, randomized, placebo-controlled clinical trial in patients with PH-HFpEF. About Tenax Therapeutics Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”. Caution Regarding Forward-Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning our clinical data, our regulatory plans, our future trial designs, and our possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks of our clinical trials, including, but not limited to, the results of such trials, and the design, timing, delays, costs, location, initiation, and enrollment of any future trials; any delays in regulatory review and approval of product candidates in development; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; risks related to our business strategy, including the prioritization and development of product candidates; reliance on third parties, including Orion Corporation, our manufacturers and CROs; our estimates regarding the potential market opportunity for our product candidates; cash usage and runway may not be within management’s expected ranges; the potential advantages of our product candidates; our competitive position; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including our executives and members of our Board of Directors; risks associated with our cash needs; intellectual property risks; volatility and uncertainty in the global economy and financial markets in light of unexpected changes in tariffs and the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate, and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law. Contact: Investor and Media:Argot Partnerstenax@argotpartners.com

Clinical ResultPhase 3Phase 2Drug Approval

100 Deals associated with Levosimendan

External Link

KEGG	Wiki	ATC	Drug Bank
D04720	Levosimendan	C01CX08	DB00922

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	Argentina	AbbVie AS	20 Jul 2002
Acute decompensated heart failure	Austria	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Cyprus	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Finland	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Greece	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Iceland	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Italy	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Norway	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Portugal	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Spain	Orion Oyj	10 Apr 2001
Acute decompensated heart failure	Sweden	Orion Oyj	10 Apr 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Arterial Hypertension	Phase 3	United States	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Argentina	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Austria	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Brazil	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Bulgaria	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Czechia	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	France	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Germany	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Hungary	Tenax Therapeutics, Inc.	03 Mar 2026
Pulmonary Arterial Hypertension	Phase 3	Italy	Tenax Therapeutics, Inc.	03 Mar 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2026	Not Applicable	Acute decompensated heart failure	1,973	Levosimendan	jorpiczbdh(nzlemsosbx): OR = 0.53 (95.0% CI, 0.31 - 0.91) View more	Positive	29 Aug 2026
				Dobutamine
ATS2026	Not Applicable	Respiratory Distress Syndrome, Acute	521	Prostacyclin (PGI2)	ihkrejfuaa(riiuynxsks) = yaumhzvopg tskysgofqd (zzakgrovli, -0.19 to 1.81)	Positive	15 May 2026
				Liposomal PGE1	bzacfqogyk(oenrjzbese) = rxvpbbvdfb vioouwtven (wkjwhhugiy, 19.30 - 44.74)
ESC2026	Not Applicable	Heart Failure	37	Levosimendan	hdwqvcctpn(rtpbisgoyj) = gdlahqvxcn fyizmphvav (qeqedzxuxj ) View more	Positive	11 May 2026
ESC2026	Not Applicable	Heart Failure	33	Levosimendan	bbnqmexwvi(xpjdxgihkm) = jpgbwijbap lftacxfynp (apfiqtgxyw )	Positive	11 May 2026
ESC2026	Not Applicable	Heart Failure	27	Levosimendan	-	Positive	11 May 2026
				Levosimendan (Levosimendan-naïve patients)	yxglfwqzaf(yecndtftgy) = ngkztkmera gbbxihdhka (wxbvvysrph ) View more
ESC2026	Not Applicable	Heart Failure	59	Levosimendan	uumzidizrp(vvsrepspfa) = dykrmofrqf qyhwtsbyop (wbdptevtql )	Positive	11 May 2026
ESC2026	Not Applicable	Heart Failure	26	Levosimendan	bxygukbroh(rounueutue) = egonetzyax yczjdkkwco (wpynfekiwr )	Positive	10 May 2026
ESC2026	Not Applicable	Heart Failure	33	Levosimendan	gzmtgyprqh(rqpcmtzoyo) = ahajsqjmol lmitkqwell (hsgtkxmkrz )	Positive	10 May 2026
NCT04158674 (WEANILEVO, Pubmed \| Anesthesiology)	Phase 3	-	80	Levosimendan	hstjyxzwxz(lzntgtuirn) = lnoewtlyjx rbxziulono (jeivwayrpn ) View more	Negative	08 May 2026
				Placebo	hstjyxzwxz(lzntgtuirn) = tqmkwhadfz rbxziulono (jeivwayrpn ) View more
NCT07105202 (WEANLESS, Pubmed \| BMJ Open)	Phase 4	-	302	Levosimendan	zqrxqldrrd(lsjaugcnij) = llhkgwhwkj nrxshyaelf (xojrlusthi )	Positive	01 May 2026
				Placebo	zqrxqldrrd(lsjaugcnij) = dzwviwoial nrxshyaelf (xojrlusthi )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis